Genedx holdings CFO Kevin Feeley sells shares worth $18,248

In recent filings with the Securities and Exchange Commission, GeneDx Holdings Corp. (NASDAQ:WGS) disclosed that its Chief Financial Officer, Kevin Feeley, has sold shares amounting to $18,248. The transaction, which took place on October 29, involved the sale of 274 shares at a price of $66.60 each. This sale was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs). Following this transaction, Feeley holds 44,951 shares of GeneDx Holdings' Class A common stock.

In other recent news, genomic testing leader GeneDx reported a significant increase in revenue for Q3 2024, hitting $76 million, a 52% rise from the previous year. This marks the first time the company has achieved profitability, a noteworthy milestone in its financial trajectory. GeneDx's growth was highlighted in its earnings call, with emphasis on its strategic expansion in the pediatric outpatient market and advancements in genomic testing offerings.

The company has sequenced over 700,000 clinical exomes and genomes, capturing 80% of the U.S. exome market. GeneDx raised its full-year 2024 revenue guidance to between $284 million and $290 million. Moreover, a partnership with Epic is planned to integrate genomic testing into major health systems in 2025.

Recent developments include a decrease in prior period collections to $6.3 million, down from $7 million, and the retirement of 70% of its test menu to focus on high-margin tests with clear reimbursement pathways. However, GeneDx leads the genomic newborn screening market with a nearly 4% positivity rate in the Guardian study and an increase in the average selling price for exome and genome tests to $3,100, a $500 increase year-over-year. The company expects continued growth in testing volumes and revenues, with plans to enhance its offerings in the NICU setting and increase genetic testing utilization among pediatric neurologists.

InvestingPro Insights

While GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley's recent share sale was relatively small and for tax purposes, it's worth examining the company's current financial position and market performance to provide context for investors.

According to InvestingPro data, GeneDx Holdings has experienced remarkable stock price appreciation, with a staggering 4373.12% return over the past year. This exceptional performance is further highlighted by the company's 387.4% price return over the last six months, indicating strong momentum in the stock.

Despite the impressive stock performance, InvestingPro Tips suggest that the company is not currently profitable, with analysts not anticipating profitability this year. This is reflected in the negative P/E ratio of -28.29 for the last twelve months as of Q3 2023. However, the company's revenue growth remains robust, with a 44.22% increase in quarterly revenue for Q3 2023.

It's important to note that while the stock has shown significant returns, an InvestingPro Tip indicates that the RSI suggests the stock is in overbought territory. This could signal potential for a price correction in the near term.

For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for GeneDx Holdings, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.